Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Wenjin Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-8374-8922; OpenAlex author ID A5100517483. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2024: 2 papers · 2025: none · 2026: 1 paper

Papers 3

  1. Radiotherapy followed by metformin neoadjuvant therapy drives superior pancreatic cancer ferroptosis and augments anti-tumor immunity. Co-author DOI 10.1016/j.fmre.2025.12.010↗
  2. Metformin Reverses Radiotherapy-Induced Pancreatic Cancer Cell Senescence by Alleviating the Unfolded Protein Response Co-author DOI 10.22541/au.172458216.61587476/v1↗
  3. Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy. First author DOI 10.7150/jca.92502↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Han Zhang · 1 shared paper, 2024 · strength 0.28
  2. Hsiang‐i Tsai · 1 shared paper, 2024 · strength 0.28
  3. Xin Wang · 1 shared paper, 2026 · strength 0.27
  4. Dongqing Wang · 1 shared paper, 2026 · strength 0.27
  5. Xiang Liao · 1 shared paper, 2026 · strength 0.27
  6. Haitao Zhu · 1 shared paper, 2026 · strength 0.27
  7. Qiang Liu · 1 shared paper, 2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.